Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. You are cautioned that forward-looking statements are inherently uncertain. Ĭertain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development and the commercial potential of CRISPR/Cas9 gene editing technologies. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need.
The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Novak has served as CRISPR Therapeutics’ CEO since its founding in 2013.ĬRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. Rodger Novak will continue to serve on the board of directors of both CRISPR as well as Casebia, CRISPR’s 50/50 joint venture with Bayer AG, and will serve as President of CRISPR Therapeutics AG, the Swiss parent company of the CRISPR group. We congratulate Sam on this new role and look forward to his future success.”ĭr. “After a deliberate and thoughtful succession process, the board of directors believes that Sam has the strategic vision and organizational acumen to drive the Company’s long-term strategy. Anthony Coles, Chairman of the CRISPR Therapeutics Board of Directors. We thank him for this leadership and look forward to his continued contributions with the board," said Dr. "CRISPR Therapeutics has become the preeminent gene editing company under Rodger’s outstanding direction. Kulkarni played a leading role in the establishment of its key collaborations with Vertex and Bayer, financing the company’s operations through its IPO, and overseeing U.S. During his tenure, both as President and Chief Business Officer, Dr. Kulkarni joined CRISPR Therapeutics in the company’s early stages as Chief Business Officer and has taken on positions of increasing responsibility, most recently serving as President of CRISPR Therapeutics Inc.
Therefore, the Board and I are confident in Sam’s ability to guide CRISPR through the next phase of the company’s evolution.”ĭr. “Sam is an exceptional executive and has been instrumental in the maturation of the company since joining us in 2015.
#CEO OF ECRISPER TRIAL#
Today CRISPR is well positioned to file a clinical trial application for its lead program in β-thalassemia by the end of the year and begin clinical trials in 2018,” said Dr. “Leading CRISPR from inception into a global company with over 100 team members in just four years has been a rewarding experience and a privilege. Rodger Novak, M.D., co-founder and current Chief Executive Officer of CRISPR Therapeutics, is stepping down from his current role for personal reasons but will continue to serve as a member of the Company’s board of directors and as an officer of its Swiss parent company, CRISPR AG. Kulkarni will assume the role effective December 1, 2017. Samarth Kulkarni, Ph.D., currently President of CRISPR Therapeutics, Inc., has been promoted to the role of Chief Executive Officer. 02, 2017 (GLOBE NEWSWIRE) - CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced today that Dr. ZUG, Switzerland and CAMBRIDGE, Mass., Oct. to Chief Executive Officer Company President to assume CEO role effective December 1, 2017 CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D.
0 kommentar(er)
